Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Case Summary For VistaGen Therapeutics, Inc. (VSTA) 0 comments
    Apr 4, 2013 5:33 PM | about stocks: VSTA

    VistaGen Therapeutics is a California biotechnology company focused primarily on the use of its proprietary pluripotent stem cell technology to discover, rescue, and develop novel drug candidates for a wide range of diseases.

    The core of the company's strategy is the use of its Human Clinical Trials in a Test Tube stem cell based platform that is designed to function as a superior assay system for determining heart or liver toxicity right in the laboratory, prior to lengthy and expensive animal tests or clinical trials. With this advanced and accurate technology, exclusive to VistaGen, the company plans to identify and develop a broad pipeline of drug rescue variants from small molecule drug candidates that were shelved due to toxicity concerns but which can now be re-evaluated and potentially modified to generate variants that are both effective and safe.

    Such a technology, once perfected, represents a potentially massive market due to the astronomical costs involved in developing and bringing a new drug to market, a process that can burn through billions of dollars for a single drug. After investing so much time and money, it's not unusual for a drug to ultimately fail due to toxicity issues that didn't show up in early testing. All of this has put the pharmaceutical industry under tremendous pressure, slowing the approval process, reducing drug pipelines, and threatening billions of dollars in market share.

    VistaGen's advanced cell technology represents significant leverage in the development process, a leverage the company intends to use to help the pharmaceutical recover prior investment in discontinued drugs with positive efficacy data. The company believes that each such drug will have the potential to be a new drug candidate in which they can have economic participation rights (upfront and development milestone payments and royalties on commercial sales).

    For additional information, visit VistaGen.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: VSTA
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.